Differential targeting of immune-cells by Pixantrone in experimental myasthenia gravis

Journal of Neuroimmunology

Volumn 258, Issue 1-2, 2013, Pages 41-50

  Marolda, Roberta ^a   Ruocco, Chiara ^a,b   Cordiglieri, Chiara ^a   Toscani, Chiara ^a   Antozzi, Carlo ^a   Mantegazza, Renato ^a   Baggi, Fulvio ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Acetylcholine receptor (AChR); Experimental autoimmune myasthenia gravis (EAMG); Immunomodulation; Pixantrone

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; PIXANTRONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BIOASSAY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG TARGETING; FEMALE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MALE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; CELL DIFFERENTIATION; FEMALE; ISOQUINOLINES; LYMPHOCYTES; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; MYELOID PROGENITOR CELLS; RATS; RATS, INBRED LEW; REAL-TIME POLYMERASE CHAIN REACTION; TOPOISOMERASE II INHIBITORS;

EID: 84876724870     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.02.021     Document Type: Article

References (33)

1. Aharonov A., Tarrab-Hazdai R., Silman I., Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 1977, 14:129-137.
2. Baggi F., Annoni A., Ubiali F., Milani M., Longhi R., Scaioli W., Cornelio F., Mantegazza R., Antozzi C. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J. Immunol. 2004, 172:2697-2703.
3. Baggi F., Antozzi C., Toscani C., Cordiglieri C. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?. Arch. Immunol. Ther. Exp. (Warsz.) 2012, 60:19-30.
4. Cavalcante P., Bernasconi P., Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr. Opin. Neurol. 2012, 25:621-629.
5. Cavaletti G., Cavalletti E., Crippa L., Di Luccio E., Oggioni N., Mazzanti B., Biagioli T., Sala F., Sala V., Frigo M., Rota S., Tagliabue E., Stanzani L., Galbiati S., Rigolio R., Zoia C., Tredici G., Perseghin P., Dassi M., Riccio P., Lolli F. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. 2004, 151:55-65.
6. Christadoss P., Poussin M., Deng C. Animal models of myasthenia gravis. Clin. Immunol. 2000, 94:75-87.
7. Cohen B.A., Mikol D.D. Mitoxantrone treatment of multiple sclerosis: safety considerations. Neurology 2004, 63:S28-S32.
8. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006, 116:2843-2854.
9. Conway D., Cohen J.A. Combination therapy in multiple sclerosis. Lancet Neurol. 2010, 9:299-308.
10. Cordiglieri C., Odoardi F., Zhang B., Nebel M., Kawakami N., Klinkert W.E., Lodygin D., Luhder F., Breunig E., Schild D., Ulaganathan V.K., Dornmair K., Dammermann W., Potter B.V., Guse A.H., Flugel A. Nicotinic acid adenine dinucleotide phosphate-mediated calcium signalling in effector T cells regulates autoimmunity of the central nervous system. Brain 2010, 133:1930-1943.
11. De Isabella P., Palumbo M., Sissi C., Capranico G., Carenini N., Menta E., Oliva A., Spinelli S., Krapcho A.P., Giuliani F.C., et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol. 1995, 48:30-38.
12. Fambrough D.M., Drachman D.B., Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 1973, 182:293-295.
13. Ghalie R.G., Edan G., Laurent M., Mauch E., Eisenman S., Hartung H.P., Gonsette R.E., Butine M.D., Goodkin D.E. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002, 59:909-913.
14. Gomez A.M., Willcox N., Molenaar P.C., Buurman W., Martinez-Martinez P., De Baets M.H., Losen M. Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?. Ann. N. Y. Acad. Sci. 2012, 1274:48-59.
15. Gonsette R.E. Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis. Expert. Opin. Pharmacother. 2007, 8:1103-1116.
16. Hehir M.K., Burns T.M., Alpers J., Conaway M.R., Sawa M., Sanders D.B. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010, 41:593-598.
17. Heinemann S., Bevan S., Kullberg R., Lindstrom J., Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:3090-3094.
18. Im S.H., Barchan D., Maiti P.K., Fuchs S., Souroujon M.C. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J. Immunol. 2001, 166:6893-6898.
19. Janssen S.P., Phernambucq M., Martinez-Martinez P., De Baets M.H., Losen M. Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil. J. Neuroimmunol. 2008, 201-202:111-120.
20. Kao I., Drachman D.B. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 1977, 196:527-529.
21. Karachunski P.I., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J. Immunol. 2000, 164:5236-5244.
22. Kumar V., Kaminski H.J. Treatment of myasthenia gravis. Curr. Neurol. Neurosci. Rep. 2011, 11:89-96.
23. Lindstrom J., Einarson B., Tzartos S. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 1981, 74(Pt C):432-460.
24. Mantegazza R., Bonanno S., Camera G., Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr. Dis. Treat. 2011, 7:151-160.
25. Martinelli V., Cocco E., Capra R., Salemi G., Gallo P., Capobianco M., Pesci I., Ghezzi A., Pozzilli C., Lugaresi A., Bellantonio P., Amato M.P., Grimaldi L.M., Trojano M., Mancardi G.L., Bergamaschi R., Gasperini C., Rodegher M., Straffi L., Ponzio M., Comi G., Italian Mitoxantrone G. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011, 77:1887-1895.
26. Mazzanti B., Biagioli T., Aldinucci A., Cavaletti G., Cavalletti E., Oggioni N., Frigo M., Rota S., Tagliabue E., Ballerini C., Massacesi L., Riccio P., Lolli F. Effects of Pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis. J. Neuroimmunol. 2005, 168:111-117.
27. Nessi V., Nava S., Ruocco C., Toscani C., Mantegazza R., Antozzi C., Baggi F. Naturally occurring CD4+CD25+ regulatory T cells prevent but do not improve experimental myasthenia gravis. J. Immunol. 2010, 185:5656-5667.
28. Pettengell R., Coiffier B., Narayanan G., de Mendoza F.H., Digumarti R., Gomez H., Zinzani P.L., Schiller G., Rizzieri D., Boland G., Cernohous P., Wang L., Kuepfer C., Gorbatchevsky I., Singer J.W. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012, 13:696-706.
29. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997, 18:263-266.
30. Souroujon M.C., Brenner T., Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity 2010, 43:446-460.
31. Srokowski T.P., Liebmann J.E., Modiano M.R., Cohen G.I., Pro B., Romaguera J.E., Kuepfer C., Singer J.W., Fayad L.E. Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort. Cancer 2011, 117:5067-5073.
32. Ubiali F., Nava S., Nessi V., Longhi R., Pezzoni G., Capobianco R., Mantegazza R., Antozzi C., Baggi F. Pixantrone (BBR2778) reduces the severity of experimental autoimmune myasthenia gravis in Lewis rats. J. Immunol. 2008, 180:2696-2703.
33. Weigle W.O., Romball C.G. CD4+ T-cell subsets and cytokines involved in peripheral tolerance. Immunol. Today 1997, 18:533-538.